Johnson Financial Group LLC Purchases New Position in Immunome, Inc. (NASDAQ:IMNM)

Johnson Financial Group LLC acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $212,000.

Several other institutional investors have also recently made changes to their positions in IMNM. Janus Henderson Group PLC boosted its holdings in Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after buying an additional 302,916 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after acquiring an additional 237,497 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after acquiring an additional 144,557 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after acquiring an additional 85,580 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Insider Activity

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.60% of the company’s stock.

Immunome Stock Performance

Shares of Immunome stock opened at $9.67 on Wednesday. The stock has a market capitalization of $771.44 million, a P/E ratio of -1.19 and a beta of 1.90. Immunome, Inc. has a 52-week low of $8.93 and a 52-week high of $30.96. The stock’s 50-day simple moving average is $10.44 and its 200 day simple moving average is $12.25.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Piper Sandler reduced their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Stephens initiated coverage on shares of Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $28.60.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.